Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Medscape journal of medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 19008986PMCID PMC2580090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adherence to interferon-beta treatment and results of therapy switching.

  2007cited by this paper
• Pharmacist intervention to improve medication adherence in heart failure: a randomized trial.

  2007cited by this paper
• Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model

  2007cited by this paper
• Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis.

  2006cited by this paper
• Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis

  2005cited by this paper
• Twenty‐four‐month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®)

  2005cited by this paper
• Adherence to medication.

  2005cited by this paper
• Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns

  2005cited by this paper
• Lipoatrophy in Patients with Multiple Sclerosis on Glatiramer Acetate

  2004cited by this paper
• Localized Panniculitis and Subsequent Lipoatrophy with Subcutaneous Glatiramer Acetate (Copaxone®) Injection for the Treatment of Multiple Sclerosis

  2004cited by this paper
• Strategies for managing the side effects of treatments for multiple sclerosis

  2004cited by this paper
• A systematic review of adherence with medications for diabetes.

  2004cited by this paper
• Long-term interferon-beta treatment for multiple sclerosis.

  2003cited by this paper
• Predictors of Adherence to Glatiramer Acetate Therapy in Individuals with Self‐Reported Progressive Forms of Multiple Sclerosis*

  2003cited by this paper
• Interrupted therapy

  2003cited by this paper
• Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and infection anxiety on adherence and ability to self-inject

  2001cited by this paper
• Predictors of Adherence to Copaxone Therapy in Individuals with Relapsing‐Remitting Multiple Sclerosis*

  2001cited by this paper
• Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.

  1999cited by this paper
• Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment

  1996cited by this paper

• Fatigue relief in multiple sclerosis by personalized neuromodulation: A multicenter pilot study [FaremusGE].

  2025cites this paper
• Sentiments of Individuals with Interstitial Cystitis/Bladder Pain Syndrome Toward Pentosan Polysulfate Sodium: Infodemiology Study

  2025cites this paper
• Vague sensations. About the background and consequences of discordance between actual and perceived physiological changes.

  2024cites this paper
• Autoinjectors for Administering Glatiramer Acetate in Relapsing Remitting Multiple Sclerosis in Europe: A Survey of Patient and Nurse Preferences

  2024cites this paper
• [Adherence to treatment in the management of patients with multiple sclerosis].

  2024cites this paper
• Feasibility of Hypnotherapy in Fatigue and Sleep Disturbance Management in Patients with Multiple Sclerosis Disease

  2024cites this paper
• “Lupus Doesn’t Have Me, I Have Lupus”: Using Patient-Centered Interviews to Understand Medication Nonadherence

  2024cites this paper
• Exploring the experience of multiple sclerosis patients in Turkey: Insights from a national survey

  2024cites this paper
• Patient adherence to an oral rehydration solution intervention to prevent dehydration following ileostomy creation: A qualitative study.

  2024cites this paper
• Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study

  2023cites this paper
• Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges

  2023cites this paper
• Assessment of medication adherence among Lebanese adult patients with non-communicable diseases during COVID-19 lockdown: a cross-sectional study

  2023cites this paper
• Effect of an educational intervention based on the theory of planned behavior on improving medication adherence in patients with multiple sclerosis treated with injectable disease-modifying drugs: randomized controlled trial

  2023cites this paper
• Between empathy and anger: healthcare workers’ perspectives on patient disengagement from antiretroviral treatment in Khayelitsha, South Africa - a qualitative study

  2023cites this paper
• Explaining the Barriers to Adherence to Treatment Regimens in Multiple Sclerosis Patients: A Qualitative Content Analysis

  2023cites this paper
• Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey.

  2023cites this paper
• The Wahls Behavior Change Model for Complex Chronic Diseases: A Clinician’s Guide

  2022cites this paper
• Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT

  2022cites this paper
• Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria

  2022cites this paper
• Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

  2022influential citation
• Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis

  2022cites this paper
• Patients' Perception of the Use of the EasyPod™ Growth Hormone Injector Device and Impact on Injection Adherence: A Multi-Center Regional Study

  2022cites this paper
• Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study.

  2022cites this paper
• Medication nonadherence: health impact, prevalence, correlates and interventions

  2022cites this paper
• Individual and Community-Level Characteristics and Adherence to Specialty Medications

  2022cites this paper
• DNND_A_370173 111..125

  2022cites this paper
• A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva® PSP

  2022cites this paper
• Enhancing Mood, Cognition, and Quality of Life in Pediatric Multiple Sclerosis

  2021cites this paper
• Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network

  2021cites this paper
• Moving forward.

  2021cites this paper
• Adherencia al tratamiento con inmunomoduladores inyectables en pacientes con esclerosis múltiple y trastorno cognitivo

  2021cites this paper
• Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care.

  2021cites this paper
• Association between multiple sclerosis disease severity and adherence to disease-modifying therapies

  2021cites this paper
• The Dark Side of Body Sensations

  2021cites this paper
• Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management

  2021cites this paper
• Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs

  2021cites this paper
• Uncorrected Proof ) Title : Adverse Drug Reactions of Multiple Sclerosis Disease-Modifying Drugs

  2021cites this paper
• Adherence to treatment with injectable immunomodulators in patients with multiple sclerosis and cognitive disorder

  2021cites this paper
• Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis

  2021cites this paper
• Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry

  2020cites this paper
• Validation of the functional assessment of chronic illness therapy - General treatment satisfaction (FACIT-TS-G) in multiple sclerosis.

  2020cites this paper
• Adherence to Medications among Outpatient Adults With Multiple Sclerosis in Medina Province in KSA (Cross-Sectional Study)

  2020cites this paper
• Site-specific PEGylation of interferon beta-1b

  2020cites this paper
• Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

  2019cites this paper
• Experiences of people with Multiple Sclerosis using textured insoles: an interpretive phenomenological exploration

  2019cites this paper
• The Effect of Pilates Training and Electrical Stimulation on Motor and Cognitive Function of Women with Multiple Sclerosis

  2019cites this paper
• Effect of risk propensity on treatment understanding and decisions in MS patients

  2019cites this paper
• [The pegylated form of interferon beta in the treatment of multiple sclerosis].

  2019cites this paper
• Physician Behavior Change: A Systematic Review.

  2019cites this paper
• Adherence and long-term outcomes of growth hormone therapy with easypod™ in pediatric subjects: Spanish ECOS study

  2019cites this paper
• “Taming the Beast”: Exploring the Lived Experience of Relapsing Remitting Multiple Sclerosis Using a Life History Approach

  2019influential citation
• Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmacies.

  2019cites this paper
• Mobile Health (mHealth) Applications and Self Healthcare Management: Willingness of Female Patients Living in Rural Areas to Static Mobile Apps

  2019cites this paper
• Mobile Applications for Multiple Sclerosis: a Focus on Self-Management

  2019cites this paper
• Long Term Compliance for MS Patients in Treatment with Disease Modifying Drugs (DMDs)

  2019cites this paper
• Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria

  2018cites this paper
• Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study

  2018cites this paper
• Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis

  2018cites this paper
• Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study)

  2018cites this paper
• Adherence to Anticholinergic Therapy and Clean Intermittent Self-Catheterization in Patients With Multiple Sclerosis

  2018cites this paper
• Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

  2018cites this paper
• Evolving Landscape of Multiple Sclerosis in India: Challenges in the Management

  2018cites this paper
• Adherencia terapéutica: factores modificadores y estrategias de mejora

  2018influential citation
• Treatment with relaxin reduces disease symptoms and enhances neuroprotection and remyelination in murine experimental autoimmune encephalomyelitis

  2018cites this paper
• Assessment of Non-adherence of Multiple Sclerosis Patients to Medication and Follow up Clinic

  2018influential citation
• Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study

  2018cites this paper
• Risk knowledge of people with relapsing-remitting multiple sclerosis – Results of an international survey

  2018cites this paper
• Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany

  2018cites this paper
• Abordaje cualitativo y cuantitativo de la adherencia a los tratamientos farmacológicos

  2017influential citation
• Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study.

  2017cites this paper
• Improved treatment satisfaction after switching therapy to rituximab in relapsing–remitting MS

  2017cites this paper
• Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

  2017influential citation
• Measuring Adherence and Outcomes in the Treatment of Patients With Multiple Sclerosis

  2017cites this paper
• Validating the Modified Drug Adherence Work-Up (M-DRAW) Tool to Identify and Address Barriers to Medication Adherence

  2017cites this paper
• Syddansk Universitet The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis

  2017cites this paper
• The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis

  2017cites this paper
• Testing the health promotion model for adherence and quality of life in individuals with multiple sclerosis

  2017cites this paper
• Impact of fampridine on quality of life: clinical benefit in real-world practice

  2017cites this paper
• Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis

  2017cites this paper
• A Health 4.0 Based Approach Towards the Management of Multiple Sclerosis

  2017cites this paper
• Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines

  2016cites this paper
• Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study

  2016cites this paper
• Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey

  2016cites this paper
• Health 4.0: The case of multiple sclerosis

  2016cites this paper
• A Systematic Review of Patients’ Perspectives on the Subcutaneous Route of Medication Administration

  2016cites this paper
• Adherence to Disease-Modifying Therapies for Multiple Sclerosis

  2016cites this paper
• Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines

  2016cites this paper
• Using EP50 to forecast treatment adherence in individuals with multiple sclerosis.

  2016cites this paper
• Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.

  2016cites this paper
• Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis

  2016cites this paper
• Biopsychosocial comparison of adherent versus nonadherent multiple sclerosis patients

  2016cites this paper
• Brain health: time matters in multiple sclerosis.

  2016cites this paper
• Jak poprawić stopień przestrzegania zaleceń terapeutycznych i jakość współpracy lekarz - pacjent

  2016cites this paper
• The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction

  2016cites this paper
• The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences

  2015influential citation
• California Health Benefits Review Program Analysis of California Assembly Bill AB 339 Outpatient Prescription Drugs

  2015cites this paper
• GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.

  2015cites this paper
• Identification of clinician challenges in order to drive the development of competency-based education: results from an international needs assessment in multiple sclerosis

  2015cites this paper
• Acceptance of the Extracare Program by Beta Interferon-Treated Patients With Multiple Sclerosis

  2015cites this paper
• Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study

  2015cites this paper